{"url_path":"/sec/dftx/8-k/2026-05-12/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1813814/0001193125-26-218251-index.html","accession_number":"0001193125-26-218251","cik":"0001813814","ticker":"DFTX","issuer_name":"Definium Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1813814/0001193125-26-218251-index.html","primary_entity_key":"0001813814","primary_entity_name":"Definium Therapeutics, Inc."},"word_count":77,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\nExhibit No.\n\nDescription\n\n99.1\n\n[Press Release, dated May 12, 2026](dftx-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nDEFINIUM THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nMay 12, 2026\n\nBy:\n\n/s/ Robert Barrow\n\n \n\n \n\n \n\nName: Robert Barrow\nTitle: Chief Executive Officer"}